Stifel Financial Corp Has $11.24 Million Position in Astrazeneca PLC (AZN)
Stifel Financial Corp boosted its position in shares of Astrazeneca PLC (NYSE:AZN) by 53.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 360,447 shares of the company’s stock after buying an additional 125,093 shares during the period. Stifel Financial Corp’s holdings in Astrazeneca PLC were worth $11,242,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Doheny Asset Management CA purchased a new position in shares of Astrazeneca PLC during the first quarter worth about $218,000. M&T Bank Corp boosted its position in shares of Astrazeneca PLC by 3.7% in the first quarter. M&T Bank Corp now owns 318,619 shares of the company’s stock worth $9,922,000 after buying an additional 11,299 shares during the period. Brandes Investment Partners LP purchased a new position in shares of Astrazeneca PLC during the first quarter worth about $7,373,000. Private Advisor Group LLC boosted its position in shares of Astrazeneca PLC by 155.4% in the first quarter. Private Advisor Group LLC now owns 61,228 shares of the company’s stock worth $1,663,000 after buying an additional 37,251 shares during the period. Finally, Bank Hapoalim BM purchased a new position in shares of Astrazeneca PLC during the first quarter worth about $1,335,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE:AZN) opened at 34.54 on Friday. The company’s 50-day moving average is $33.27 and its 200-day moving average is $29.95. The company has a market cap of $87.46 billion, a P/E ratio of 25.87 and a beta of 0.81. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.27.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, April 27th. The company reported $0.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.61. The business had revenue of $5.41 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. The firm’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.95 EPS. On average, analysts anticipate that Astrazeneca PLC will post $1.86 EPS for the current fiscal year.
A number of brokerages recently issued reports on AZN. Leerink Swann reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Astrazeneca PLC in a research note on Wednesday, May 17th. Credit Suisse Group raised shares of Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research note on Friday, May 12th. Jefferies Group LLC restated a “hold” rating on shares of Astrazeneca PLC in a research report on Monday, April 10th. HSBC Holdings plc lowered shares of Astrazeneca PLC from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. Finally, Liberum Capital initiated coverage on shares of Astrazeneca PLC in a research report on Thursday, March 9th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $35.84.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.